Vertex receives European CHMP positive opinion for KALYDECO® (ivacaftor) to treat CF
Vertex Pharmaceuticals announces the EMA’s Committee for Medicinal Products for Human Use adopted a positive opinion for KALYDECO® (ivacaftor) to include treatment of people with cystic fibrosis aged 12 to <24 months who have at least one of nine mutations in their CFTR gene. October 19, 2018